Innovative Cancer Treatments to be Produced in Ukraine
Ukraine will start producing innovative drugs to combat cancer diseases.
The press service of the state enterprise "Medical Procurements" announced that an agreement with the international pharmaceutical company Roche on localizing the production of innovative cancer medications was signed at the Ukraine Recovery Conference in Rome.
"For the first time, our state enterprise is becoming a full partner of a global leader in innovative drug development! According to the investment agreement, the Swiss company Roche will supply ready-to-package medications to Ukraine, and we will handle their final packaging and labeling," the statement said.
This will significantly reduce the cost of medications and consequently increase the number of patients receiving modern treatment.
"According to Roche's estimates, within 5 years, the signed investment agreement will provide medications for over 5,800 patients," said the enterprise "Medical Procurements".
In particular, medications will be procured for the two most common types of cancer in Ukraine:
- atezolizumab ("Tecentriq") - for treating non-small cell lung cancer;
- pertuzumab + trastuzumab ("Phesgo") - for treating HER2-positive breast cancer.
Ukrainian patients will be able to access these locally produced drugs as early as 2027.
This collaboration will also lead to a significant reduction in drug costs, the development of pharmaceutical production in Ukraine, and sustainable access to treatment.
On July 10-11, the fourth International Conference on Ukraine Recovery is taking place in Rome, attended by the President of Ukraine and leaders of European states.
The forum will continue a series of high-level political events dedicated to the rapid recovery and long-term reconstruction of Ukraine, which is suffering from external aggression. This time, the Ukrainian delegation will focus on presenting practical projects that are already being implemented even during the war or are highly prepared for implementation.
